RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07827261, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0;

    Inclusion criterion 9

    Prior treatment with drugs targeting KRAS G12C;

    Exclusion criterion 1

  3. ECOG performance status score ≤1;

    Inclusion criterion 8

  4. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5×ULN;

    Inclusion criterion 12

  5. Must have at least one measurable lesion as defined by RECIST v1.1;

    Inclusion criterion 7

  6. Diagnosis of active malignancy within 5 years before randomization in the study;

    Exclusion criterion 14

  7. Pregnant or breastfeeding women;

    Exclusion criterion 27

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07827261, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form and comply with protocol requirements;
  • No restriction on gender;
  • Age ≥18 years and ≤75 years;
  • Expected survival time ≥3 months;
  • Patients with locally advanced or metastatic non-small cell lung cancer;
  • Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 2 years, or fresh tissue samples;
  • Must have at least one measurable lesion as defined by RECIST v1.1;
  • ECOG performance status score ≤1;
  • Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0;
  • No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
  • Organ function levels must meet the requirements;
  • Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5×ULN;
  • Urine protein ≤1+ or <1000 mg/24 h;
  • For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy testing must exclude pregnancy, and the patient must be non-lactating; all enrolled patients (regardless of male or female) should use adequate barrier contraception throughout the entire treatment period and for 7 months after treatment completion.

Exclusion Criteria:

  • Prior treatment with drugs targeting KRAS G12C;
  • Prior use of ADC drugs with small-molecule toxins as topoisomerase I inhibitors;
  • Coexisting other known oncogenic driver gene mutations that can be targeted therapeutically;
  • Prior history of intestinal disease or major gastric surgery;
  • Participation in any other clinical trial within 4 weeks before the first administration of this trial;
  • History of severe heart disease or cerebrovascular disease;
  • Receipt of radical radiotherapy, major surgery, extensive radiotherapy, etc., within 4 weeks before randomization in the study;
  • Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;
  • QTc interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
  • History of interstitial lung disease/interstitial pneumonia treated with steroids, etc.;
  • Concurrent pulmonary disease leading to clinically severe impairment of respiratory function;
  • Severe infection occurring within 4 weeks before randomization in the study;
  • Patients at risk of active autoimmune disease, or patients with a history of autoimmune disease;
  • Diagnosis of active malignancy within 5 years before randomization in the study;
  • Positive human immunodeficiency virus antibody, active tuberculosis, active syphilis, active hepatitis B virus infection, or hepatitis C virus infection;
  • Hypertension poorly controlled with two antihypertensive drugs;
  • Patients with poorly controlled blood glucose;
  • Presence of a large amount of serous cavity effusion, or serous cavity effusion with obvious symptoms caused by the serous cavity effusion, etc.;
  • Active central nervous system metastasis;
  • Imaging examination suggesting that the tumor has invaded or encased the abdomen, chest, etc.;
  • Severe and unhealed wounds, ulcers, or fractures within 4 weeks before signing informed consent;
  • Trial participants with clinically obvious bleeding or a clear bleeding tendency within 4 weeks before signing informed consent;
  • History of allogeneic stem cell, bone marrow, or organ transplantation;
  • Patients with a history of allergy to recombinant humanized antibodies or allergy to any excipient component of BL-B01D1;
  • History of severe neurological or psychiatric disease;
  • History of autologous or allogeneic stem cell transplantation;
  • Pregnant or breastfeeding women;
  • Trial participants planning to receive vaccination or who received a live vaccine within 28 days before randomization in the study;
  • Other circumstances in which the investigator considers it inappropriate to participate in this clinical trial.

Quoted from ClinicalTrials.gov, NCT07827261, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07827261, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07827261